Currently, there are four FDA-approved immunotherapy drugs for use in patients with advanced or metastatic melanoma: ipilimumab, an inhibitor of CTLA-4; pembrolizumab and nivolumab, both inhibitors of PD-1; and atezolizumab, an inhibitor of PD-L1. This evidence concerns the gene CD274 and metastatic melanoma.